公开(公告)号：US20150299182A1

公开(公告)日：2015-10-22

申请号：US14441133

申请日：2013-11-08

Applicant: Array BioPharma Inc. ,  Amgen Inc.

Inventor： Sylvie Asselin ,  Lisa Brett ,  Ying Chen ,  Donald T. Corson ,  Andrew Cosbie ,  Robert Farrell ,  Indrani W. Gunawardana ,  Jinkun Huang ,  Jonathan W. Lane ,  Dennis Lei ,  Christopher M. Lindemann ,  Van Luu ,  Coralee G. Mannila ,  Robert Milburn ,  Henry Morrison ,  Helming Tan ,  Jason Tedrow ,  Daniel J. Watson

IPC: C07D417/14

CPC classification number: C07D417/14 ,  C07B2200/13

Abstract: The present invention relates to crystalline polymorph forms of (1S)-1-[5-({3-[(2-methylpyridin-3-yl)oxy]-5-(pyridin-2-ylsulfanyl)pyridin-2-yl}amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol, to pharmaceutical compositions comprising such crystalline polymorph forms, and to processes for preparing them. The invention further relates to methods of treatment of diabetes related disorders comprising administering such solid-state forms or compositions thereof to a subject, and to use of such crystalline polymorph forms in the manufacture of medicaments.

Abstract translation: 本发明涉及（1S）-1- [5 - （{3 - [（2-甲基吡啶-3-基）氧基] -5-（吡啶-2-基硫烷基）吡啶-2-基} 氨基）-1,2,4-噻二唑-3-基]乙烷-1,2-二醇，包括这种结晶多晶型物的药物组合物及其制备方法。 本发明还涉及治疗糖尿病相关病症的方法，包括将这种固态形式或其组合物施用于受试者，以及在制备药物中使用这种结晶多晶型物。

公开(公告)号：US20210077493A1

公开(公告)日：2021-03-18

申请号：US16942094

申请日：2020-07-29

Applicant: Array BioPharma Inc.

Inventor： Donald T. Corson ,  Christopher M. Lindemann ,  Daniel J. Watson

IPC: A61K31/517 ,  A61K31/437 ,  A61P35/00 ,  C07D471/04 ,  A61K45/06

Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5 -a]pyridin-7-yloxy)-3 -methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.

公开(公告)号：US20180140603A1

公开(公告)日：2018-05-24

申请号：US15861444

申请日：2018-01-03

Applicant: Array BioPharma Inc.

Inventor： Donald T. Corson ,  Christopher M. Lindemann ,  Daniel J. Watson

IPC: A61K31/517 ,  A61K45/06 ,  C07D471/04

CPC classification number: A61K31/517 ,  A61K31/437 ,  A61K45/06 ,  A61P35/00 ,  C07D471/04

Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.

公开(公告)号：US09278936B2

公开(公告)日：2016-03-08

申请号：US14382178

申请日：2013-02-27

Applicant: Array BioPharma Inc.

Inventor： Alisha B. Arrigo ,  Donald T. Corson ,  Coralee G. Mannila

IPC: C07D231/56 ,  A61K31/4155

CPC classification number: C07D231/56 ,  A61K31/4155 ,  Y02A50/411 ,  Y02A50/463

Abstract: Provided herein is a hydrogen chloride salt of 1-(3-/t?r/-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea, crystalline forms of 1-(3-½^butyl-1^-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride, processes for the preparation of said crystalline forms, pharmaceutical compositions containing a crystalline form of 1-(3-r

Abstract translation: 本文提供的是1-（3-叔丁基-1-叔丁基-1-对甲苯基-1H-吡唑-5-基）-3-（5-氟-2-（1-（2 - 羟基乙基）-1H-吲唑-5-基氧基）苄基）脲，1-（3 - 1/2丁基-1'-甲苯基-1H-吡唑-5-基）-3-（5-氟-2 - （1-（2-羟乙基）-1H-吲唑-5-基氧基）苄基）脲盐酸盐，制备所述结晶形式的方法，含有1-（3-r 丁基-1-对甲苯基-1H-吡唑-5-基）-3-（5-氟-2-（1-（2-羟乙基）-1H-吲唑-5-基氧基）苄基）脲盐酸盐形式B ，所述组合物的制备方法，通过所述方法制备的药物组合物，以及所述组合物在治疗各种疾病和病症中的用途。

公开(公告)号：US11571424B2

公开(公告)日：2023-02-07

申请号：US16942094

申请日：2020-07-29

Applicant: Array BioPharma Inc.

Inventor： Donald T. Corson ,  Christopher M. Lindemann ,  Daniel J. Watson

IPC: A61K31/517 ,  A61K31/437 ,  A61P35/00 ,  C07D471/04 ,  A61K45/06

Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.

公开(公告)号：US20160175309A1

公开(公告)日：2016-06-23

申请号：US14923172

申请日：2015-10-26

Applicant: Array BioPharma Inc.

Inventor： Donald T. Corson ,  Christopher M. Lindemann ,  Daniel J. Watson

IPC: A61K31/517 ,  A61K45/06

CPC classification number: A61K31/517 ,  A61K31/437 ,  A61K45/06 ,  A61P35/00 ,  C07D471/04

Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.

Abstract translation: N 4 - （4 - （[1,2,4]三唑并[1,5-a]吡啶-7-基氧基）-3-甲基苯基）-N6-（4,4-二甲基-4,5-二氢恶唑-2-基） 吡啶-2-基）喹唑啉-4,6-二胺。 还公开了制备多晶型物的方法和包含多晶型物的药物组合物。

公开(公告)号：US20230241066A1

公开(公告)日：2023-08-03

申请号：US18092731

申请日：2023-01-03

Applicant: Array BioPharma Inc.

Inventor： Donald T. Corson ,  Christopher M. Lindemann ,  Daniel J. Watson

IPC: A61K31/517 ,  A61P35/00 ,  C07D471/04 ,  A61K31/437 ,  A61K45/06

CPC classification number: A61K31/517 ,  A61P35/00 ,  C07D471/04 ,  A61K31/437 ,  A61K45/06

Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.

公开(公告)号：US20190125749A1

公开(公告)日：2019-05-02

申请号：US16169937

申请日：2018-10-24

Applicant: Array BioPharma Inc.

Inventor： Donald T. Corson ,  Christopher M. Lindemann ,  Daniel J. Watson

IPC: A61K31/517 ,  A61K45/06 ,  A61K31/437 ,  A61P35/00 ,  C07D471/04

Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4, 5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.

公开(公告)号：US09889134B2

公开(公告)日：2018-02-13

申请号：US14923172

申请日：2015-10-26

Applicant: Array BioPharma Inc.

Inventor： Donald T. Corson ,  Christopher M. Lindemann ,  Daniel J. Watson

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/517 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K31/517 ,  A61K31/437 ,  A61K45/06 ,  A61P35/00 ,  C07D471/04

Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.

公开(公告)号：US10765678B2

公开(公告)日：2020-09-08

申请号：US16169937

申请日：2018-10-24

Applicant: Array BioPharma Inc.

Inventor： Donald T. Corson ,  Christopher M. Lindemann ,  Daniel J. Watson

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/517 ,  A61P35/00 ,  A61K45/06

Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.